SCHEMBL3584560

SCHEMBL3584560

CNc1cc(-n2nc(C)cc2Nc2cc(NC(=O)c3cc(N4CCN(C(=O)OC(C)(C)C)CC4)cc(C(F)(F)F)c3)ccc2C)ncn1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LYN P07948 7/20 0.48
LCK P06239 7/20 0.48
KDR P35968 7/20 0.48
BRAF P15056 6/20 0.48
SRC P12931 6/20 0.48
INSR P06213 5/20 0.48
HCK P08631 5/20 0.48
MAP3K7 O43318 1/20 0.46
MAP4K2 Q12851 1/20 0.46
CSF1R P07333 4/20 0.46
RAF1 P04049 1/20 0.45
MAPK14 Q16539 2/20 0.42
TEK Q02763 1/20 0.41
KDM4E B2RXH2 1/20 0.41
POLB P06746 1/20 0.41
RECQL P46063 1/20 0.41
MEN1 O00255 1/20 0.40
MAPT P10636 1/20 0.40
TSHR P16473 1/20 0.40
KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3577157 0.91 LCK (0.42) LYNLCKKDRBRAFSRC
SCHEMBL3589623 0.90 LYN (0.59) LYNLCKKDRBRAFSRC
SCHEMBL3591200 0.88 LYN (0.60) LYNLCKKDRBRAFSRC
SCHEMBL3588042 0.88 LYN (0.50) LYNLCKKDRBRAFSRC
SCHEMBL3590781 0.88 CSF1R (0.58) LYNLCKKDRBRAFSRC
SCHEMBL3581781 0.88 LYN (0.52) LYNLCKKDRBRAFSRC
SCHEMBL3591708 0.88 LYN (0.50) LYNLCKKDRBRAFSRC
SCHEMBL3585891 0.88 LYN (0.53) LYNLCKKDRBRAFSRC
SCHEMBL3591813 0.88 LYN (0.51) LYNLCKKDRBRAFSRC
SCHEMBL3592421 0.88 CSF1R (0.58) LYNLCKKDRBRAFSRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8202876-B2 Compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2012-06-19 US claimed
US-20100029605-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2010-02-04 US claimed
EP-2057146-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2009-05-13 EP claimed
WO-2008042639-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2008-04-10 WO claimed
US-8202876-B2 Compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2012-06-19 US disclosed
US-8202876-B2 Compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2012-06-19 US disclosed
US-20100029605-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2010-02-04 US disclosed
US-20100029605-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2010-02-04 US disclosed
EP-2057146-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2009-05-13 EP disclosed
WO-2008042639-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2008-04-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029605-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS FYN, ABL2, LCK LYN 12/4885LCK 3/4885KDR 13/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.